Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

North Shore University Hospital / Division of Infectious Diseases, Manhasset

Dupont Circle Physician's Group, Washington D.C.

Whitman-Walker Health, Washington D.C.

Capital Medical Associates, PC, Washington D.C.

Duke University Medical Center, Durham

ID Consultants, P.A., Charlotte

University of South Carolina School of Medicine Division of Infectious Disease, Columbia

Infectious Disease Specialists of Atlanta, Decatur

Mercer University Mercer Medicine, Macon

Orlando Immunology Center, Orlando

IDOCF/ValuhealthMD, LLC, Orlando

Wohlfeiler, Piperato and Associates, LLC, Miami Beach

Gary J. Richmond,M.D.,P.A., Fort Lauderdale

St. Joseph's Comprehensive Research Institute, Tampa

University of Alabama at Birmingham (UAB), Birmingham

Be Well Medical Center, Berkley

Henry Ford Health System, Detroit

Hennepin County Medical Center, Minneapolis

Howard Brown Health Center, Chicago

Central West Clinical Research Inc, St Louis

Southwest Infectious Disease Clinical Research Inc, Dallas

DCOL Center for Clinical Research, Longview

Tarrant County Infectious Disease Associates, Fort Worth

Therapeutic Concepts, PA, Houston

Gordon E. Crofoot, MD., PA, Houston

Apex Research, LLC, Denver

Spectrum Medical Group, Phoenix

Kaiser Permanente, Los Angeles

Peter J. Ruane, MD, Inc., Los Angeles

Anthony Mills MD, Inc, Los Angeles

AHF Research Center, Beverly Hills

La Playa Medical Group and Clinical Research, San Diego

St. Joseph Heritage Healthcare, Orange

Metropolis Medical, San Francisco

Kaiser Permanente Medical Group-Clinical Trials Unit, San Francisco

Stanford University, Palo Alto

East Bay AIDS Center, Oakland

Kaiser Permanente Medical Group, Sacramento

Peter Shalit, M.D., Seattle

Brigham and Women's Hospital, Boston

Clinical Research Puerto Rico, San Juan